$600,000 Granted in the First-Ever Research Awards Funded by ALK Positive

alk-positive-lungevity-fundraising.jpg

read the full press release here

ALK-positive lung cancer patients take matters into their own hands to fund research with the potential to save their lives

Each of these two-year awards is for up to $200,000, with monies raised by ALK Positive and Lungevity. The three projects selected aim to understand how immunotherapy can be used for ALK-positive patients.

These new projects, which will uncover why immunotherapy has not been successful in treating ALK-positive lung cancer and test new immunotherapy approaches in ALK-positive lung cancer, include:

  • Characterization of anti-ALK immunologic responses in ALK-positive NSCLC: Mark Awad, MD, PhD, Dana-Farber Cancer Institute

  • Overcoming innate immune resistance in ALK-rearranged lung cancer: Justin Gainor, MD, Massachusetts General Hospital

  • Targeting the complement pathway in ALK positive lung cancer: Raphael Nemenoff, PhD, University of Colorado Denver, AMC and DC

 

Tom Carrollimmunotherapy, research, lungevity